BE2022C501I2 - - Google Patents

Download PDF

Info

Publication number
BE2022C501I2
BE2022C501I2 BE2022C501C BE2022C501C BE2022C501I2 BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2 BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2
Authority
BE
Belgium
Application number
BE2022C501C
Other languages
French (fr)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BE2022C501I2 publication Critical patent/BE2022C501I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BE2022C501C 2003-01-29 2022-01-03 BE2022C501I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003020854 2003-01-29

Publications (1)

Publication Number Publication Date
BE2022C501I2 true BE2022C501I2 (en) 2023-03-07

Family

ID=32820637

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2022C501C BE2022C501I2 (en) 2003-01-29 2022-01-03

Country Status (26)

Country Link
US (4) US7300935B2 (en)
EP (1) EP1591446B1 (en)
KR (1) KR101074462B1 (en)
CN (2) CN100360538C (en)
AU (1) AU2004207706B2 (en)
BE (1) BE2022C501I2 (en)
BR (1) BRPI0407082C1 (en)
CA (1) CA2514407C (en)
CO (1) CO5590921A2 (en)
CY (2) CY1114008T1 (en)
DK (1) DK1591446T3 (en)
ES (1) ES2410814T3 (en)
FR (1) FR21C1056I2 (en)
HU (1) HUS2100052I1 (en)
IL (1) IL169869A (en)
LT (1) LTC1591446I2 (en)
MX (1) MXPA05007990A (en)
NL (1) NL301158I2 (en)
NO (2) NO331981B1 (en)
NZ (1) NZ541772A (en)
PL (1) PL214756B1 (en)
PT (1) PT1591446E (en)
RU (1) RU2331648C2 (en)
SI (1) SI1591446T1 (en)
WO (1) WO2004067535A1 (en)
ZA (1) ZA200506611B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
ES2494842T3 (en) * 2005-07-22 2014-09-16 Takeda Pharmaceutical Company Limited Agent that prevents early ovulation
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
WO2010026993A1 (en) 2008-09-03 2010-03-11 武田薬品工業株式会社 Method for improving absorbability of preparation, and preparation having improved absorbability
KR101430424B1 (en) * 2009-01-08 2014-08-14 쿠리스 인코퍼레이션 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
EP3111938B1 (en) 2011-04-01 2019-05-08 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ES2767956T3 (en) * 2011-11-11 2020-06-19 Gilead Apollo Llc ACC inhibitors and their uses
CN104703992B (en) * 2012-09-28 2019-03-05 武田药品工业株式会社 Preparation method of thienopyrimidine derivatives
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP2881391A1 (en) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
MY180680A (en) 2015-02-26 2020-12-06 Takeda Pharmaceuticals Co Solid preparation
CN107922609B (en) 2015-07-01 2020-04-24 加州理工学院 Delivery system based on cationic mucic acid polymers
AR106472A1 (en) 2015-10-26 2018-01-17 Gilead Apollo Llc ACC INHIBITORS AND USES OF THE SAME
BR112018010453B1 (en) 2015-11-25 2022-06-14 Gilead Apollo, Llc ACETYL COA CARBOXYLASE (ACC) INHIBITOR TRIAZOLIC COMPOUNDS
CA3004747A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine
PT3380480T (en) 2015-11-25 2023-03-14 Gilead Apollo Llc Pyrazole acc inhibitors and uses thereof
JP2018536660A (en) 2015-11-25 2018-12-13 ギリアド アポロ, エルエルシー Ester ACC inhibitors and uses thereof
RU2610281C1 (en) * 2016-02-26 2017-02-08 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) Method for production of 2-fluorine-3-methylbut-2-enyl amine or its hydrochloride (versions)
US10183951B2 (en) 2016-03-02 2019-01-22 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
CN110312512B (en) 2016-09-30 2023-05-09 梦欧文科学有限责任公司 Methods for treating uterine fibroids and endometriosis
WO2018060463A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Treatment of prostate cancer
PT3600309T (en) 2017-03-28 2022-10-03 Gilead Sciences Inc Therapeutic combinations for treating liver diseases
JP7348171B2 (en) 2017-06-05 2023-09-20 キッセイ薬品工業株式会社 Gonadotropin-releasing hormone antagonist dosing regimen for the treatment of endometriosis
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
EP3806887A4 (en) 2018-06-13 2022-04-06 California Institute of Technology BLOOD-BRAIN BARRIER CROSSING NANOPARTICLES AND METHODS OF TREATMENT THEREOF
MX2021002742A (en) 2018-09-11 2021-08-11 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety.
EP3873465B1 (en) 2018-10-29 2025-01-15 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
KR20210100623A (en) 2018-11-07 2021-08-17 옵스에파 에스에이 Compositions and methods for the treatment of estrogen-dependent disorders
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
US20220220123A1 (en) * 2019-05-15 2022-07-14 Dr. Reddy's Laboratories Limited Amorphous and crystalline forms of relugolix
CN110194776B (en) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 Synthetic method of Ruogeli
US20220267347A1 (en) * 2019-07-29 2022-08-25 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
WO2021026011A1 (en) * 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112321602A (en) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 Preparation method of Ruogeli drug intermediate
WO2021023877A2 (en) 2019-08-08 2021-02-11 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CA3150089A1 (en) 2019-08-08 2021-02-11 ObsEva S.A. Gnrh antagonists for the treatment of estrogen-dependent disorders
CN112390812A (en) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 Crystalline and amorphous solids of Ruogeli compounds and methods of making the same
CN112771052B (en) * 2019-08-21 2023-04-07 深圳仁泰医药科技有限公司 Crystal form of gonadotropin releasing hormone antagonist and preparation method and application thereof
EP4041739A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN112745304A (en) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 Preparation method of Relugolix and intermediate compound
CN113444105A (en) * 2020-03-27 2021-09-28 南京海润医药有限公司 Preparation method of Relugolix
CN111333633B (en) * 2020-04-01 2023-10-20 江西科睿药业有限公司 Intermediate compound of Rayleigh Lu Geli and preparation method and application thereof
CN111574534B (en) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 Phenyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use
IL298587A (en) 2020-05-29 2023-01-01 Myovant Sciences Gmbh Combination of solid oral dosage forms of gonadotropin-releasing hormone antagonists
CN111793078B (en) * 2020-07-03 2022-02-01 东莞市东阳光新药研发有限公司 Bicyclic nitrogen-containing heteroaryl substituted pyrimidinediones and application thereof
CN111875614B (en) * 2020-07-03 2022-04-29 东莞市东阳光新药研发有限公司 Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use
CN111925379B (en) * 2020-07-31 2022-02-15 广东东阳光药业有限公司 Nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof
CN111909168B (en) * 2020-07-31 2022-02-01 广东东阳光药业有限公司 Nitrogenous heterocyclic group substituted pyrimidinediones and uses thereof
CN112047957B (en) * 2020-09-09 2022-02-01 广东东阳光药业有限公司 Substituted pyrimidinediones and their use
CN113754679B (en) * 2020-09-09 2023-04-07 广东东阳光药业有限公司 Substituted pyrimidinediones and their use
CN112142757B (en) * 2020-09-29 2022-02-15 广东东阳光药业有限公司 Five-membered nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN112552312B (en) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 Synthetic method of Ruogeli or salt thereof
CN113620972A (en) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 Rugosril new crystal form and preparation method thereof
CN114907370B (en) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 High purity thienopyrimidine compounds and process for their preparation
CN115073491A (en) * 2021-03-12 2022-09-20 上海医药工业研究院 Rugosril intermediate, preparation method and application thereof
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
CN113135934A (en) * 2021-04-28 2021-07-20 北京海美源医药科技有限公司 Intermediate compound for preparing Ruugeli, preparation method of intermediate compound and preparation method of Ruugeli
CN115260211B (en) * 2021-04-29 2024-02-06 长春金赛药业有限责任公司 Thiophene condensed ring derivative, pharmaceutical composition, preparation method and application thereof
EP4419530A1 (en) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
JP2024540264A (en) * 2021-11-01 2024-10-31 シャンドン ルイ ファーマシューティカル カンパニー リミテッド Gonadotropin-releasing hormone antagonists and their preparation and use
CN114230576A (en) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 A kind of preparation method of Relugoli
CN114989134B (en) * 2022-07-14 2023-11-14 江西同和药业股份有限公司 Thiophene compound and preparation method and application thereof
CN115417883B (en) * 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 Crystal form of rui Lu Geli and preparation method thereof
WO2024126674A1 (en) 2022-12-15 2024-06-20 Medichem, S.A. Process for the preparation of relugolix
WO2024222827A1 (en) * 2023-04-27 2024-10-31 山东绿叶制药有限公司 Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048863A (en) * 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
UY23948A1 (en) 1995-02-08 2001-10-25 Takeda Chemical Industries Ltd DERIVATIVES FROM THYPHENE CONDENSED RINGS, THEIR PRODUCTION AND USE.
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
US6297379B1 (en) * 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
JP2001316391A (en) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd Method for producing thienopyridine derivative
KR20030005205A (en) * 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 Processes for the production of thienopyrimidine derivatives
US20030134863A1 (en) * 2000-04-13 2003-07-17 Shuichi Furuya Preventives/remedies for alzheimer's disease
JP2001354588A (en) * 2000-04-13 2001-12-25 Takeda Chem Ind Ltd Prophylactic and therapeutic agent for alzheimer disease
CA2407472A1 (en) * 2000-06-14 2002-10-23 Takeda Chemical Industries, Ltd. Sustained release compositions
JP2002068982A (en) * 2000-06-14 2002-03-08 Takeda Chem Ind Ltd Sustained release composition
JP2002080397A (en) * 2000-07-05 2002-03-19 Takeda Chem Ind Ltd Therapeutic pharmaceutical formulation for sex hormone-dependent disease
US20030176360A1 (en) 2000-07-05 2003-09-18 Yasutaka Igari Medicinal preparations for treating sex hormone-dependent diseases
WO2002024230A1 (en) * 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Solid preparations
JP2002167327A (en) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd Solid formulation
WO2002043766A1 (en) * 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Medicinal compositions and process for producing the same
AU2002221139A1 (en) * 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
EP1370562A1 (en) * 2001-02-14 2003-12-17 Warner-Lambert Company LLC Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
JP5072166B2 (en) * 2002-01-30 2012-11-14 武田薬品工業株式会社 Thienopyrimidine compound, production method and use thereof
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
AU2003211877A1 (en) 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
JP2004002321A (en) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd Therapeutic agent for sex hormone dependent disease
JP2004002377A (en) * 2002-04-12 2004-01-08 Takeda Chem Ind Ltd Hot flash preventing and treating agent
AU2003236039A1 (en) 2002-04-12 2003-10-27 Takeda Pharmaceutical Company Limited Preventives/remedies for hotflash

Also Published As

Publication number Publication date
LTC1591446I2 (en) 2023-04-25
HUS2100052I1 (en) 2021-12-28
EP1591446A1 (en) 2005-11-02
US8058280B2 (en) 2011-11-15
MXPA05007990A (en) 2005-09-20
NO331981B1 (en) 2012-05-21
CA2514407C (en) 2012-01-03
CN101153042A (en) 2008-04-02
KR20050096171A (en) 2005-10-05
CO5590921A2 (en) 2005-12-30
PT1591446E (en) 2013-06-12
US20080108623A1 (en) 2008-05-08
WO2004067535A1 (en) 2004-08-12
RU2331648C2 (en) 2008-08-20
EP1591446A4 (en) 2008-04-30
PL214756B1 (en) 2013-09-30
FR21C1056I1 (en) 2022-01-21
CA2514407A1 (en) 2004-08-12
ZA200506611B (en) 2006-12-27
HK1084665A1 (en) 2006-08-04
BRPI0407082A (en) 2006-01-24
NZ541772A (en) 2009-10-30
KR101074462B1 (en) 2011-10-18
US20060160829A1 (en) 2006-07-20
IL169869A (en) 2011-10-31
RU2005127052A (en) 2006-02-10
DK1591446T3 (en) 2013-06-10
ES2410814T3 (en) 2013-07-03
US20140221381A1 (en) 2014-08-07
LTPA2021529I1 (en) 2021-12-10
BRPI0407082B8 (en) 2019-06-25
US7300935B2 (en) 2007-11-27
CN1768065A (en) 2006-05-03
PL378002A1 (en) 2006-02-20
EP1591446B1 (en) 2013-03-06
NO20053974D0 (en) 2005-08-25
NL301158I2 (en) 2022-05-25
AU2004207706A1 (en) 2004-08-12
US8735401B2 (en) 2014-05-27
CY2021039I2 (en) 2022-03-24
CY2021039I1 (en) 2022-03-24
SI1591446T1 (en) 2013-07-31
CN100360538C (en) 2008-01-09
CY1114008T1 (en) 2016-07-27
US9346822B2 (en) 2016-05-24
NO20053974L (en) 2005-10-27
US20120071486A1 (en) 2012-03-22
BRPI0407082B1 (en) 2019-06-04
AU2004207706B2 (en) 2010-03-04
BRPI0407082C1 (en) 2021-05-25
NO2021052I1 (en) 2021-12-16
FR21C1056I2 (en) 2022-11-18

Similar Documents

Publication Publication Date Title
BE2022C501I2 (en)
BE2013C075I2 (en)
BE2013C069I2 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
BE2011C030I2 (en)
BE2013C034I2 (en)
JP2003271400A5 (en)
JP2004005419A5 (en)
BE2012C053I2 (en)
JP2004182218A5 (en)
JP2004000632A5 (en)
JP2003288198A5 (en)
JP2004034026A5 (en)
DK200200343U3 (en)
JP2004215922A5 (en)
AU2002351829A1 (en)
AU2002353888A1 (en)
AU2002327042A1 (en)
AU2003210772A1 (en)
AU2003207787A1 (en)
AU2002327736A1 (en)
AU2002329412A1 (en)
AU2003207750A1 (en)